TB-500 (Thymosin Beta-4): What the Research Actually Shows
TB-500 is a synthetic seven-amino-acid peptide that copies the actin-binding region of thymosin beta-4, a protein released by platelets, macrophages and other cells when tissue is injured. Interest in TB-500 comes from laboratory and animal work on cell migration, blood vessel formation, tendon biomechanics and wound closure, not from human clinical trials: no human pharmacokinetic or safety study of TB-500 itself appears in the sources reviewed for this article, and the peptide is sold strictly as a research chemical. This guide covers what the molecule is, how its mechanism is described in peer-reviewed literature, what animal studies actually measured, how tb-500 dosage appears in research papers and supplier listings, and how tb-500 reconstitution and storage should be handled. None of it is medical advice or a dosing instruction for human use.
Related searches: tb 500, tb-500 dosage, thymosin beta 4, tb-500 reconstitution, tb-500 peptide, tb-500 half life, thymosin beta-4 fragment.
What TB-500 Is and Where It Comes From
Thymosin beta-4 (Tb4) is a naturally occurring polypeptide of 43 amino acids with a molecular weight of about 5 kDa. It is the most abundant member of the beta-thymosin family in mammalian tissue and is regarded as the main G-actin sequestering peptide in cells. After injury it is released by platelets and macrophages, where it is described as protecting cells and tissues from further damage and reducing apoptosis, inflammation and microbial growth.
TB-500 is not that whole protein. It is the N-acetylated fragment Ac-LKKTETQ, a heptapeptide that corresponds to the actin-binding site of thymosin beta-4 and amounts to roughly one sixth of the parent sequence. Because the two names are used interchangeably online, searches for thymosin beta 4 return both the full-length protein, which has been studied in skin, eye, heart and brain research programmes, and the shorter fragment sold as TB-500. The distinction matters when reading study data: most tissue-repair experiments in the literature used the full protein, while the fragment has a much thinner evidence base of its own. The spaced spelling tb 500 and the hyphenated tb-500 refer to the same fragment, and catalogue entries typically list both so that either query resolves.
Dragon Pharma supplies the fragment as a lyophilised TB-500 (thymosin beta-4) 5 mg vial for reconstitution with bacteriostatic water, and also offers it pre-combined with BPC-157 in a single vial.
Mechanism: Actin Balance, Cell Migration and Angiogenesis
Actin is the protein that gives a cell its shape and lets it move. Cells keep a reserve of free globular actin (G-actin) monomers that can be polymerised into filaments on demand, and sequestering peptides such as thymosin beta-4 bind those monomers, regulating how much actin remains available for filament assembly. That balance sits underneath cell motility, and motility is what allows repair cells to reach a damaged area.
The actin-binding motif is not decorative. Using natural thymosin beta-4, proteolytic fragments and synthetic peptides, researchers found that a seven-amino-acid actin-binding motif was essential for the molecule's angiogenic activity. In migration assays with human umbilical vein endothelial cells and in vessel sprouting assays using chick aortic arches, thymosin beta-4 and its actin-binding motif showed near-identical activity at about 50 nM, while peptides missing any part of the motif were inactive. Adhesion to thymosin beta-4 was blocked by the same seven-amino-acid peptide, identifying it as the major cell binding site on the molecule.
Two further effects are described in review literature. After injury, thymosin beta-4 promotes cell migration and the mobilisation and differentiation of stem and progenitor cells that form new blood vessels and regenerate tissue. It also reduces the number of myofibroblasts in wounds, which is associated with less scar formation and fibrosis.
Two limits of the mechanism are worth keeping in view. First, angiogenesis and cell migration are not automatically beneficial: the same signalling is involved in the growth of unwanted tissue and blood vessels, so more activity is not the same as a better outcome. Second, the intracellular actin-sequestration explanation is considered unlikely to account for every reported effect, because that would require the peptide to be taken up by cells.
Animal Data and the TB-500 Dosage Used in Research
The most concrete recent data on the fragment comes from a rat tendon model. Thirty-two male Sprague-Dawley rats had their Achilles tendon transected and repaired, then received intraperitoneal treatment for four weeks in four groups: control, BPC-157 at 10 mcg/kg/day, TB-500 at 60 mcg/kg/day, and both peptides combined.
- Biomechanics - maximum load to failure was higher in both peptide groups than in controls, and the difference reached statistical significance in the TB-500 group (p less than 0.05)
- Histology - total Bonar scores were significantly lower in the TB-500 group (p = 0.016), and total Movin scores were significantly lower in the TB-500 and combination groups (p = 0.017 and p = 0.040), which the authors read as improved tendon architecture, better collagen alignment and fewer degenerative changes
- Collagen staining - Sirius red birefringence analysis showed increased type I collagen signal in treated tendons, consistent with a more mature repair matrix
- Metabolism in rats - after dosing, the primary metabolite Ac-LK reached its highest concentration in the 0 to 6 hour window, while the metabolite Ac-LKK behaved as a long-term marker and was still detectable in urine up to 72 hours
- In vitro activity - neither the parent peptide nor its metabolites were cytotoxic in fibroblast assays, and one metabolite, Ac-LKKTE, showed significant wound-healing activity compared with control, which led the authors to suggest that some previously reported activity of TB-500 may belong to its breakdown products rather than to the parent molecule
Read together, these findings describe a plausible repair mechanism plus measurable effects in rodents. They do not establish efficacy, dose or safety in humans, and the doses used in animals are not transferable to people.
There is no established human dose of TB-500, because there is no published human dose-finding study. What exists is a research dose in animals and a set of supplier protocols written for research-chemical customers. Both are useful reference points and neither is a medical recommendation.
| Source | Amount | Frequency | Context |
|---|---|---|---|
| Rat Achilles tendon study | 60 mcg/kg/day | Daily, 4 weeks | Intraperitoneal, animal research dose |
| Dragon Pharma product listing | 2 to 2.5 mg | Twice weekly, 4 to 6 weeks | Loading phase published for research use |
| Dragon Pharma product listing | 2 to 2.5 mg | Once weekly, ongoing | Maintenance phase published for research use |
| Vial size | 5 mg lyophilised powder | Not applicable | Concentration depends on diluent volume added |
Two practical points follow from this table. First, animal doses are expressed per kilogram of body weight and cannot be scaled to a person by simple arithmetic. Second, the loading-then-maintenance schedule above is a supplier convention for a research product, not a clinical protocol, and it should be read as documentation rather than guidance. Any use of TB-500 outside laboratory research is unapproved, and the peptide is not intended for human consumption.
TB-500 Reconstitution and Storage
TB-500 arrives as a lyophilised (freeze-dried) powder and has to be dissolved before use in research. The purpose-designed diluent is bacteriostatic water with 0.9% benzyl alcohol, which is sterile water for injection plus a preservative that inhibits bacterial growth between draws. The preservative is what makes a multi-dose vial practical: the supplier describes a reconstituted vial as usable for up to 28 days when refrigerated, whereas a peptide mixed with plain sterile water has no preservative and must be treated as single-use.
- Before opening - let the vial reach room temperature first. Lyophilised peptides are hygroscopic and absorb atmospheric moisture, which reduces the actual peptide content; keeping unopened vials cold, dry and tightly sealed protects both quantity and stability
- Adding diluent - let the bacteriostatic water run down the glass side of the vial instead of landing on the powder cake, then mix with a light swirl until the cake dissolves. Vigorous shaking is avoided because it creates foam and can damage the peptide
- Concentration - the arithmetic is simple and depends only on the diluent volume, as the table below shows for a 5 mg vial
- Storage - published peptide handling guidance puts long-term storage of the lyophilised powder below -15 degrees Celsius, with short-term storage at 4 degrees Celsius acceptable; solutions should be kept refrigerated and, if frozen, left as frozen aliquots, because repeated freeze-thaw cycles degrade peptides. Long-term storage of peptide solutions is not recommended
- Labelling - record the date of reconstitution and the concentration on the vial. Reconstitution errors are the most common reason research concentrations do not match what the protocol intended
| Diluent added to a 5 mg vial | Concentration | Volume containing 1 mg |
|---|---|---|
| 1 mL | 5 mg/mL | 0.2 mL |
| 2 mL | 2.5 mg/mL | 0.4 mL |
| 5 mL | 1 mg/mL | 1 mL |
TB-500 vs BPC-157 and Related Repair Peptides
TB-500 and BPC-157 are frequently discussed as a pair because both are studied for tissue repair, but they are different molecules with different assumed behaviour. On the same catalogue, BPC-157 is described as a 15-amino-acid pentadecapeptide derived from a protective protein found in gastric juice, with a localised action pattern in which injection site location is treated as meaningful. TB-500, by contrast, is described as acting systemically, so site selection is considered less important.
The chemical difference is real: TB-500 is a seven-amino-acid fragment of thymosin beta-4, while BPC-157 is a fifteen-amino-acid peptide from a completely different parent protein. Their mechanisms are also described differently in the literature, with BPC-157 research focused on cytoprotection and gastrointestinal and vascular signalling, and TB-500 research focused on actin sequestration, cell migration and angiogenesis. Researchers who want both mechanisms in one vial can use the BPC-157 and TB-500 peptide blend, while those working on the actin-binding mechanism alone can use the BPC-157 pentadecapeptide or TB-500 separately to keep the two variables independent.
Risks, Open Questions and Legal Status
The single most important legal fact about TB-500 is its anti-doping status. The World Anti-Doping Agency's Prohibited List places thymosin beta-4 and its derivatives, including TB-500 by name, in class S2, the class for peptide hormones, growth factors and related mimetic substances. Substances in that class are prohibited at all times, meaning in and out of competition, and a positive finding is not treated as a specified substance. Anyone subject to anti-doping rules should treat TB-500 as banned.
- Not an approved medicine - TB-500 has no approved human indication and is sold as a research chemical. Products labelled for research use are not manufactured, dosed or monitored to pharmaceutical standards for human administration
- Angiogenesis is double-edged - the same mechanism that supports new blood vessel growth in repair tissue is involved in abnormal vessel formation and unwanted tissue growth, which is why long-term exposure is a recurring question in debates about regenerative peptides
- Metabolite activity - because breakdown products of TB-500 retain biological activity, the effect of a dose cannot be assumed to match the parent peptide concentration measured in a sample
- Sourcing and cold chain - purity, sterility and correct storage cannot be verified from packaging alone. Peptides that have been warm, reconstituted incorrectly or handled without a cold chain may be degraded before they ever reach the bench
- Documentation - keep batch, order and storage records. If a result looks anomalous, handling history is the first thing to audit
For research use, the practical conclusion is that TB-500 is a well-characterised fragment with a clear mechanistic story and a modest, animal-only evidence base. Treat every figure above as documentation of what has been done in studies and listings, never as a protocol for human use.